With increased government scrutiny on telehealth and potential changes to COVID-era telehealth flexibilities on the horizon, it is critical that companies keep apprised of telehealth compliance regulations through 2024 and beyond.
The RDS program has been the go-to choice for plan sponsors who offer group coverage to retired employees, however, the Inflation Reduction Act makes it difficult now for plans to meet the creditable qualification criteria.
Biden is counting on outrage over abortion restrictions to help drive turnout for his reelection, while Trump is promising to repeal Obamacare, but where do the candidates stand on Americans' everyday health concerns?
Martin O'Malley, the new Social Security commissioner, is promising to overhaul the agency's system of clawing back $23 billion it claims was wrongly sent to beneficiaries, saying it "just doesn't seem right or fair."
Any prolonged disruption of the health care tech company's systems "will negatively impact many hospitals' ability to offer the full set of health-care services," wrote the American Hospital Association to HHS Secretary Xavier Becerra.
In states that banned abortion, doctors are forced to wrestle with tough decisions about high-risk pregnancy care and "don't want to have a patient die and be responsible for it," said one doctor.
President Biden's battle against high drug prices, part of the Inflation Reduction Act, is intended to give Medicare patients immediate relief and, in the long term, to regulate what drugmakers charge for their products.
While there is no system in place to equitably manage the patient-to-clinician ratio across every state, the system counts only physicians, not the myriad other health care professionals who now provide the nation's primary care.
The Rural Emergency Hospital program guarantees hospitals extra cash if they provide emergency and outpatient services but end inpatient care, although just 18 out of 1,700 eligible hospitals have won the new designation.
Patients who have experienced severe stomach complications from the new class of GLP-1 weight loss drugs are now suing Novo Nordisk and Eli Lilly alleging that the drugmakers misled doctors on the drugs' potential risks.